45 results about "Atractylenolide I" patented technology

The invention provides an anti-depression composition and a preparation method thereof. The composition is prepared from the following components in parts by mass: 1 part of saikoside D, 2 to 6 parts of saikoside A, 20 to 25 parts of paeoniflorin, 6 to 9 parts of albiflorin, 12 to 15 parts of apiose liquiritin, 2 to 4 parts of apiose isoliquiritin and 4 to 6 parts of atractylenolide I. Compared with western medicine fluoxetine and classic famous formula Xiaoyao powder which are sold on the market under the clinical equivalent dosage condition in the depression cell and depression animal experiment dimension, cell experiments and animal experiments both show that the medicine effect of the anti-depression composition is far higher than the anti-depression effect of the western medicine fluoxetine, and meanwhile, the anti-depression composition has the advantages that the anti-depression effect of the anti-depression composition is greatly improved. The medicine effect is higher than the anti-depression effect of the whole prescription of the Xiaoyao powder

The invention belongs to the technical field of quality control of traditional Chinese medicines, and relates to a method for simultaneously determining fingerprints and multiple components of a rhizoma atractylodis macrocephalae medicinal material and an extract of the rhizoma atractylodis macrocephalae medicinal material. The invention provides the detection method of the fingerprint spectrum of the rhizoma atractylodis macrocephalae medicinal material and the extract thereof and the construction method of the standard fingerprint spectrum, which are of great significance in enhancing qualitative and quantitative control of the rhizoma atractylodis macrocephalae and ensuring that the medicinal effect of the rhizoma atractylodis macrocephalae medicinal material is maintained in the process from production, transportation to clinical application; on the basis of the existing fingerprint spectrum research, the common peak distribution characteristics of the fingerprint spectrum of the rhizoma atractylodis macrocephalae medicinal material and the volatile oil are further determined, and an HPLC simultaneous determination method for the five components of atractylone, atractylenolides I-III and beta-caryophyllene is established by a wavelength gradient method, so that a solid foundation is laid for drawing up the quality standard of the rhizoma atractylodis macrocephalae medicinal material, the rhizoma atractylodis macrocephalae volatile oil and the preparation of the rhizoma atractylodis macrocephalae medicinal material and the rhizoma atractylodis macrocephalae volatile oil.

The invention relates to a sesquiterpenoid glycoside compound in Atractylodes lancea, and a preparation method and application thereof. The invention belongs to the technical field of medicines, and relates to a method for extracting and separating a sesquiterpenoid glycoside compound (1S, 5S, 7R, 10S)-10-hydroxy-deoxy split-ring atractylodes macrocephala delta-lactone-11-O-beta-D-glucopyranoside from rhizome of Atractylodes lancea by using normal phase silica gel, reverse phase silica gel, preparative high performance liquid chromatography and other technologies. In-vitro anti-tumor activity screening experiments show that the compound has good anti-tumor activity, including obvious inhibition effects on human lung cancer cells A549, human cervical cancer cells Hela and human liver cancer cells HepG-2. Therefore, the sesquiterpenoid glycoside compound has a prospect of being developed into antitumor drugs.

The invention belongs to the technical field of quality detection of traditional Chinese medicines, and discloses a quality detection method of rhizoma atractylodis macrocephalae fried with fructus aurantii, which is characterized by comprising the following steps: performing qualitative analysis on rhizoma atractylodis macrocephalae fried with fructus aurantii by respectively adopting a thin-layer chromatography and an HPLC (High Performance Liquid Chromatography) characteristic chromatogram; a high performance liquid phase external standard curve method is adopted to carry out quantitative analysis on atractylenolide I, atractylenolide II, atractylenolide III, naringin and neohesperidin in the fructus aurantii fried bighead atractylodes rhizome. The invention establishes a thin-layer identification method for rhizoma atractylodis macrocephalae and fructus aurantii in a fructus aurantii fried rhizoma atractylodis macrocephalae processed product; according to the method for establishing the fingerprint spectrum, the similarity of 10 batches of rhizoma atractylodis macrocephalae fried with fructus aurantii ranges from 0.991 to 1.000; the method for determining the content of atractylenolide I, atractylenolide II, atractylenolide III, naringin and neohesperidin is established, scientific support is provided for formulating the quality standard of the characteristic processing decoction pieces of the temporary prescription, and effective guarantee is provided for clinical application of the decoction pieces.

The invention provides a composite antibiotic-replacing microcapsule preparation as well as a preparation method and application thereof. The composite antibiotic-replacing microcapsule preparation comprises a core material as well as an inner-layer wall material and an outer-layer wall material which are sequentially coated outside the core material, wherein the core material comprises a Chinese herbal medicine extract, plant essential oil and probiotics, the Chinese herbal medicine extract comprises forsythin, astragalus polysaccharide and atractylenolide III, the plant essential oil comprises origanum oil and cinnamyl aldehyde, and the probiotics comprise bacillus subtilis; the inner-layer wall material is prepared by crosslinking sodium alginate and calcium chloride, and the outer-layer wall material comprises chitosan. The traditional Chinese medicine composition has the characteristics of synergistic interaction, high stability and good intestinal tract targeting property, and can improve the resistance replacement effect.

The invention belongs to the technical field of medicine detection, and particularly relates to a quality evaluation method for phlegm and fluid retention pills based on HPLC fingerprint spectrum and multi-index component content determination. The method comprises the following steps: determining the contents of nine active components in the phlegm-drinking pill and constructing an HPLC fingerprint spectrum of the phlegm-drinking pill based on a high performance liquid chromatography-high resolution mass spectrometry technology; wherein the nine active ingredients are sinapine, chlorogenic acid, cryptochlorogenic acid, 3, 6 '-dimustard acyl sucrose, rosmarinic acid, apiose isoliquiritin, isoliquiritin, glycyrrhizic acid and atractylenolide I. The invention further discloses a preparation method of the pharmaceutical composition. According to the method, the fingerprint spectrum and multi-index determination are integrated, a reproducible technical framework is provided for modern quality evaluation of the traditional Chinese medicine compound preparation with lower instrument cost and higher universality, and the industry is promoted to be transformed from'single component control 'to'overall quality management and control'.

The present invention provides a method for detecting the HPLC fingerprint of Atractylodes macrocephala. The present invention provides an Atractylodes macrocephala medicinal material, which uses the above-mentioned detection method to detect the content of four components: atractylodes lactone I, atractylodes lactone II, atractylodes lactone III, and atractylodes ketone. Each gram of Atractylodes macrocephala medicinal material contains 0.21-0.32 mg of atractylodes lactone I, 0.13-0.25 mg of atractylodes lactone II, 0.1-0.19 mg of atractylodes lactone III, and 5.21-14.08 mg of atractylodes ketone. The present invention also provides an HPLC fingerprint of Atractylodes macrocephala and a method for determining the quality of Atractylodes macrocephala medicinal material. The present invention also provides a method for screening quality-marking components of Atractylodes macrocephala medicinal material. The present invention adopts the HPLC-DAD multi-wavelength switching method to establish the HPLC fingerprint of Atractylodes macrocephala, conducts chemometric research at the same time, and determines the contents of atractylodes lactone I, atractylodes lactone II, atractylodes lactone III and atractylodesone. On the one hand, it can comprehensively evaluate the quality of Atractylodes macrocephala, provide a reference for the quality evaluation and control of Atractylodes macrocephala medicinal materials and decoction pieces, and also lay the foundation for the research on its pharmacological substance basis and related compound research; on the other hand, it can provide a reference for the improvement of the quality standard of Atractylodes macrocephala.

The application discloses a sesquiterpene derivative, a preparation method and application thereof. The application provides a novel sesquiterpene derivative which is obtained by modifying atractylodin III. Activity research shows that the sesquiterpene derivative has stronger inhibiting effect on IgE or histamine secretion than atractylodin III. It is known to those skilled in the art that allergy is mediated by IgE, and histamine secretion under the stimulation of IgE is an important cause of various allergic symptoms. Therefore, the sesquiterpene derivative provided by the application has the prospect of being developed into a medicine for preventing and / or treating diseases which are prevented and / or treated by inhibiting IgE or histamine secretion, such as allergic diseases like food allergy.

The invention discloses a multi-index content determination method of hovenia acerba and rhizoma atractylodis bowel-relaxing granules, and belongs to the technical field of traditional Chinese medicine detection. The invention establishes a high performance liquid chromatography method for simultaneously determining nine components including caffeic acid, chicoric acid, naringin, naringin, hesperidin, neohesperidin, chrysophanol, aurantio-obtusin and atractylenolide I in a preparation, and the content of the components is calculated through a relative correction factor by taking caffeic acid as an internal reference by adopting a quantitative analysis of multi-components by single marker. According to the method, effective detection of the immature bitter orange medicinal material and the immature bitter orange base source is realized, and the immature bitter orange and the sweet orange base source of the traditional Chinese medicine immature bitter orange can be accurately distinguished, so that more comprehensive and accurate quality control of the traditional Chinese medicine is realized, and the stability and consistency of clinical efficacy of the traditional Chinese medicine are guaranteed.

The invention belongs to the technical field of feed additives, and particularly discloses a composite methane inhibitor and a preparation method thereof. The composite methane inhibitor is prepared from the following raw materials in parts by weight: 16 to 21 parts of oligomeric schizophyllan, 6 to 10 parts of atractylenolide IV, 3 to 5 parts of loganin, 1 to 5 parts of mannosylerythritol lipid and 4 to 8 parts of modified montmorillonite. Experimental results show that all the components of the compound methane inhibitor cooperate with one another, and the effects of adjusting intestinal flora and reducing the methane content can be achieved. Specifically, atractylenolide IV and loganin synergistically inhibit the activity of methanogens, and oligomeric schizophyllan has antioxidant activity, so that oxidation of unsaturated fatty acid can be inhibited, and side reactions possibly promoting generation of methane are reduced; and the modified montmorillonite has relatively large interlayer spacing and specific surface area, has an excellent adsorption effect, and is beneficial to keeping activity of components such as oligomeric schizophyllan and the like, so that the inhibition effect is further enhanced.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a pharmaceutical composition containing atractylenolide, a preparation method and application, the pharmaceutical composition takes lipidosome as a carrier, and comprises lipidosome carrier components such as atractylenolide, oxaliplatin, phospholipid, cholesterol and the like and specific auxiliary components. The pharmaceutical composition is prepared by adopting a film dispersion-ultrasonic homogenization method, the water solubility of the atractylenolide is effectively improved, the bioavailability of the medicine and the stability of the preparation are improved, through the synergistic effect of the atractylenolide and the oxaliplatin, the chemotherapy-related toxic and side effects are reduced while the anti-tumor curative effect is enhanced, and the pharmaceutical composition is suitable for clinical application. The compound can be used for preparing anti-tumor drugs, and a novel efficient and low-toxicity drug scheme is provided for tumor treatment.

The present invention discloses the use of Atractylodes lactone II in the preparation of a medicament for treating diabetic retinopathy. The use of Atractylodes lactone II disclosed in the present invention in the preparation of a medicament for treating diabetic retinopathy has the following beneficial effects: 1. Through the hypoglycemic, anti-inflammatory, antioxidant, and vascular protective effects of Atractylodes lactone II, a non-invasive, multi-target treatment strategy is provided, and diabetic metabolic disorders and retinal microvascular lesions are simultaneously improved, thereby overcoming the singleness and limitations of existing technologies; 2. Atractylodes lactone II can effectively lower blood sugar in diabetic mice; 3. Atractylodes lactone II can effectively improve glucose tolerance in diabetic mice; 4. Atractylodes lactone II can alleviate vascular occlusion in the retinas of diabetic mice and make the vascular morphology of diabetic mice closer to that of control mice; 5. Atractylodes lactone II can reduce the degree of pathological damage to the retinal tissue of diabetic mice.

The invention provides a composition for treating rheumatoid arthritis, belonging to the technical field of traditional Chinese medicine preparations. Strychnine (from Strychnos nux vomica or Strychnos nux vomica extract), atractylodes lactone III (from Atractylodes macrocephala or Atractylodes macrocephala extract), tanshinone IIA (from Salvia miltiorrhiza or Salvia miltiorrhiza extract) and ligusticolide A (from Chuanxiong or Chuanxiong extract) are selected and compounded in a suitable ratio to achieve a good therapeutic effect on rheumatoid arthritis. The invention can achieve more accurate medication by accurately controlling the ratio of each effective ingredient, thereby ensuring the therapeutic effect, reducing the side effects that may be caused by excessive ingredients, and improving the safety of the drug and the tolerance of patients.

The application discloses a detection method of Yichangleng composition, and the method comprises the following steps: S1, preparation of reference solution; S2, preparation of test solution; S3, preparation of mixed control solution; S4, respectively, precisely sucking Yichangleng test solution of S2 and mixed control solution of S3; injecting into a liquid chromatograph; S5, exporting Yichangleng characteristic spectrum obtained in S4, selecting chromatographic peaks existing in chromatograms of Yichangleng solution as characteristic peaks; calculating relative peak area and relative retention time of each characteristic peak; and according to the retention time of the chromatogram of the mixed control solution, labeling the components of the peaks in the control characteristic spectrum, the method can be used for detecting gallic acid, vanillic acid, paeoniflorin, uncarine, thalictrifolin, 5-O-methylvisamminol glycoside, quercetin, kaempferol and atractylochide II, and can realize overall quality control of Yichangleng solution.

The invention discloses a pharmaceutical composition for treating type 2 diabetes mellitus and application of the pharmaceutical composition. The pharmaceutical composition for treating type 2 diabetes mellitus is prepared from atractylenolide I, catalpol, berberine, quercetin, magnolol and nobiletin according to the mass ratio of (2.5 to 7.5): (1 to 3): (5 to 20): (5 to 10): (1 to 10): (1 to 40). According to the research on the pathogenesis of type 2 diabetes mellitus and the active ingredients of traditional Chinese medicines, the active ingredients of the traditional Chinese medicines with a targeted therapeutic mechanism are screened by applying a molecular docking theory, and the composition is self-planned to be composed of various active ingredients of the traditional Chinese medicines based on the traditional Chinese medicine state target theory and clinical Pi-dan prescription application experience, and is explored in the research on the pharmacological mechanism of treating T2DM. Researches find that the pharmaceutical composition has a good T2DM treatment effect, and the action mechanism of the pharmaceutical composition is realized by improving bile acid metabolism, intestinal flora homeostasis and glucose homeostasis of liver-intestinal axes of T2DM rats.

A personal care composition comprising a carboxymethyl cysteine compound and a atractylenolide source is disclosed.

The present invention belongs to the technical field of feed additives, and specifically discloses a composite methane inhibitor and a preparation method thereof. The composite methane inhibitor comprises the following raw materials by weight: 16-21 parts of oligomeric schizophyllan, 6-10 parts of atractylodes lactone IV, 3-5 parts of loganin, 1-5 parts of mannose erythritol lipids, and 4-8 parts of modified montmorillonite. Experimental results show that the components of the composite methane inhibitor cooperate with each other to achieve the effect of regulating intestinal flora and reducing methane content. Specifically, atractylodes lactone IV and loganin synergistically inhibit the activity of methanogens, and oligomeric schizophyllan can inhibit the oxidation of unsaturated fatty acids due to its antioxidant activity, reducing side reactions that may promote methane production; and modified montmorillonite has a larger interlayer spacing and specific surface area, and has excellent adsorption, which is conducive to maintaining the activity of components such as oligomeric schizophyllan, thereby further enhancing the inhibitory effect.

The invention discloses a traditional Chinese medicine component compound preparation for treating metabolism-related fatty liver diseases and application of the traditional Chinese medicine component compound preparation. The effective components of the traditional Chinese medicine component compound preparation comprise alisol B and atractylenolide III. According to the invention, the synergistic interaction mechanism of alisol B and atractylenolide III is disclosed for the first time, and the limitation of multi-component mixing of a traditional compound is broken through. After the two components are combined according to a specific ratio, the effects of improving liver functions and lowering lipid are remarkably improved compared with those of an original formula, the scientific breakthrough of formula reduction and effect improvement is achieved, the problems that compound components are complex and quality standards are difficult to control are solved, and the traditional Chinese medicine composition has no common side effects of weight gain and other western medicines and has unique advantages in treatment of metabolism-related fatty liver diseases.

The application provides a method for screening active ingredients capable of activating TAS1R3 receptors, and belongs to the technical field of screening of active ingredients of traditional Chinese medicines. The application establishes a biosensor, and the biosensor detects the current signal after each concentration of compound solution reacts with the TAS1R3 receptor; the dissociation constant K D of the interaction between the compound and the TAS1R3 receptor is calculated according to the linear fitting equation between the common logarithm of the concentration of the compound and the current change, and the compound with the K D value in the range of 10 ‑13 -10 ‑8 M is screened as the active ingredient capable of activating the TAS1R3 receptor. In the application, the interaction dissociation constant K D of the Atractylodes lactone II and the glycyrrhizic acid with the TAS1R3 protein is 3.759*10 ‑8 M and 4.435*10 ‑9 M respectively, and the binding force with the TAS1R3 protein is very strong. Moreover, the Atractylodes lactone II and the glycyrrhizic acid have the function of improving anemia within a certain concentration, and provide a new idea for the screening of candidate compounds with the sweet characteristic and the treatment of anemia or blood deficiency syndrome in traditional Chinese medicines and the research and development of new drugs.

A whitening and spot-fading composition based on molecular docking technology and a preparation method therefor. The composition comprises atractylenolide I, pachymic acid, paeoniflorin and glabridin, wherein the mass ratio of the atractylenolide I, pachymic acid, paeoniflorin and glabridin is 50-600:100-700:600-2000:10-200. On the basis of the docking binding energy of active ingredients in four plants Atractylodes macrocephala, Paeonia lactiflora, poria cocos and licorice to a key target molecule of a disease, it is found by screening that compounding the atractylenolide I, pachymic acid, paeoniflorin and glabridin as active ingredients can obtain the composition having a remarkable whitening and spot-fading effect, the melanin synthesis inhibition rate of the composition reaches 69.4%-83.6%, and the tyrosinase activity inhibition rate of the composition reaches 76.8%-91.3%.

The invention discloses a atractylenolide synthesis intermediate and a synthesis method of atractylenolide and a derivative thereof, and the method comprises the following steps: oxidizing methyl in a compound 17 to prepare a compound 18; preparing a compound 19 from the compound 18 under the action of a Grubbs catalyst; carrying out hydrogenation reduction on the compound 19 to prepare a compound 20; dehydrating and eliminating the compound 20 to obtain a compound 21; hydrolyzing the compound 21 to obtain a compound 22; according to the invention, asymmetric total synthesis of atractylone, 13 kinds of eudecane atractylenolides and lactam natural products is finally realized, the technical bottleneck of chiral control of the compounds is broken through for the first time, the convergent design has both step economy and derivative universality, and especially, the type of a nucleophilic reagent is changed by a system, so that the method is suitable for industrial production. And derivative libraries with various structures are successfully constructed.

The invention belongs to the technical field of quality control of traditional Chinese medicines, and relates to a thin-layer chromatography identification method and application of bighead atractylodes rhizome and an extract thereof. The invention provides two thin-layer identification methods, one thin-layer identification method takes four components such as atractylenolide I, atractylenolide II, atractylenolide III and beta-eudesmol in bighead atractylodes rhizome as index components, and the other thin-layer identification method takes three components such as atractylenone, geranene B and beta-elemene in bighead atractylodes rhizome as index components. The two methods can be used for rapidly and accurately identifying the rhizoma atractylodis macrocephalae medicinal material, the rhizoma atractylodis macrocephalae volatile oil, the volatile oil clathrate and the rhizoma atractylodis macrocephalae clathrate related preparations, are mild in condition and easy to operate, are favorable for comprehensively improving the quality control level of rhizoma atractylodis macrocephalae related products, provide feasible reference for innovation and research and development related to rhizoma atractylodis macrocephalae in each stage, and have important industrial value.

The application belongs to the technical field of traditional Chinese medicine detection, and particularly relates to a method for determining seven active components in northern atractylodes medicinal materials. The method adjusts the concentrations of the control substances atractylone, atractylodin, beta-eudesmol, corynol, atractylodes lactone I, atractylodes lactone III and 5-hydroxymethyl furfural to 0.12 mg / mL, 0.21 mg / mL, 0.09 mg / mL, 0.13 mg / mL, 0.09 mg / mL, 0.06 mg / mL and 0.04 mg / mL respectively; and a single detection wavelength 203 nm is adopted. The method is simple, fast and quantitative, and can comprehensively, intuitively and more completely evaluate the efficacy of northern atractylodes.

The invention provides a method for inducing hairy roots of atractylodes macrocephala koidz and application, and belongs to the technical field of plant culture and transgenosis. Hairy roots of atractylodes macrocephala koidz are successfully cultured through the steps of optimizing culture and dilution of agrobacterium liquid, infection of explants and the like; the method lays a foundation for large-scale production of atractylone, atractylenolide and other active ingredients by using the autonomously growing atractylodes macrocephala hairy roots, and solves the problem that wild atractylodes macrocephala resources are limited. The induction and culture method for the hairy roots of the bighead atractylodes rhizome has the advantages of autonomic rapid growth and differentiation of hormones, high multiplication coefficient, stable heredity, convenience in material taking, no limitation by seasons, short culture time and the like, and has great significance in improvement of the transgenic technology of the bighead atractylodes rhizome. The method plays a positive role in mass culture of the bighead atractylodes rhizome hairy roots and biotransformation of secondary products of the bighead atractylodes rhizome hairy roots in the later period.

The invention belongs to the technical field of medicines, relates to a cineole type sesquiterpenoid glycoside compound (3R, 5S, 10S)-atractylenolide I-3-O-beta-D-glucopyranose (1-> 6)-beta-D-glucopyranoside extracted and separated from Atractylodes lancea, and discloses a method for preparing the compound and application of the compound, and the molecular formula of the compound is C26H36O12. Atractylodes lancea is used as a raw material, reflux extraction is carried out through ethanol with the mass concentration of 95%, and then separation, purification and preparation are carried out in combination with organic solvent extraction and chromatography of multiple chromatographic columns. Meanwhile, after in-vitro anti-tumor activity screening, it is found that the compound has a remarkable inhibition effect on human liver cancer (HepG-2), human gastric cancer (BGC-823) and human colon cancer (HT-29) cells, a new basis is provided for clinical application of rhizoma atractylodis guanensis to treatment of liver cancer, gastric cancer and colon cancer, and a pharmacodynamic material basis is provided for reasonable development of medicinal resources in future.

This invention discloses the application of atractylodes lactone I in the preparation of drugs for inhibiting lung metastasis of breast cancer. This invention provides a novel use for atractylodes lactone I, which can reduce the lung metastasis ability of breast cancer cells. When atractylodes lactone I is used as a drug, experiments in breast cancer-bearing mice show that atractylodes lactone I can significantly inhibit the occurrence and development of lung metastasis of breast cancer, and has no significant effect on the body weight of mice, exhibiting high safety. Therefore, atractylodes lactone I shows promise for development into a new drug for inhibiting lung metastasis of breast cancer.

The invention discloses a traditional Chinese medicine grease oral cream for repairing gastric mucosa and a preparation method thereof, optimizes a traditional heating extraction process into direct compatibility of traditional Chinese medicine extracts, and belongs to the technical field of traditional Chinese medicine preparations. The emulsifiable paste is prepared from a fixed-proportion grease base (20% of emu oil, 40% of olive oil, 20% of coconut oil and 20% of castor oil), six traditional Chinese medicine extract effective components (1-2% of astragaloside, 1-2% of atractylenolide, 1-2% of atractylenone, 1-2% of berberine, 1-2% of scutellaria baicalensis extract and 1-2% of obakunone), 3% of vitamin E, 20-25% of sea buckthorn seed oil and 10% of excipient beewax. According to the preparation process, heating extraction is abandoned, the problems that the extract is difficult to dissolve and easy to agglomerate in grease are solved through infiltrating the extract with a small amount of grease, homogenizing at the low temperature of 60 DEG C and shaping and fixing beewax, and uniform dispersion and stable dispersion of the extract are realized.

The invention provides a rhizoma atractylodis macrocephalae HPLC fingerprint spectrum, a detection method thereof and a rhizoma atractylodis macrocephalae medicinal material quality evaluation method, and relates to the technical field of medicinal material quality detection. The detection method comprises the following steps: S1, pretreating a rhizoma atractylodis macrocephalae medicinal material to obtain rhizoma atractylodis macrocephalae water decoction freeze-dried powder, adding a solvent into the rhizoma atractylodis macrocephalae water decoction freeze-dried powder, performing ultrasonic treatment, and filtering to obtain a test solution; and S2, establishing the bighead atractylodes rhizome HPLC fingerprint spectrum from the test solution by adopting an HPLC wavelength switching method. The method comprises the following steps: establishing a largehead atractylodes rhizome fingerprint spectrum, simultaneously carrying out chemometrics research, carrying out quantitative analysis of multi-components by single marker by taking atractylenolide III as an internal reference substance, establishing relative correction factors between atractylenolide III and neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, atractylenolide II and atractylenolide I, the contents of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, atractylenolide II and atractylenolide I in the atractylodes macrocephala koidz medicinal material are calculated through the relative correction factors, and the quality of the atractylodes macrocephala koidz medicinal material can be comprehensively evaluated.

The invention relates to the technical field of medicines, in particular to an anti-ulcerative colitis pharmaceutical composition containing liquiritin and atractylenolide I. The pharmaceutical composition comprises active components or pharmaceutically acceptable salts, tautomers, stereoisomers and pharmaceutic adjuvants of the active components, and the active components comprise liquiritin and atractylenolide I. The invention further provides a preparation method of the anti-ulcerative colitis pharmaceutical composition containing liquiritin and atractylenolide I. Compared with the prior art, the invention firstly discloses that the combination of liquiritin and atractylenolide I has obvious curative effects on improving intestinal tissue lesion of ulcerative colitis disease, reducing sexual cell infiltration of colitis and improving colon and cecum states of UC mice, has no toxic or side effect, is not easy to generate tolerance, and has no toxic or side effect. The discovery has great influence on the research and treatment of ulcerative colitis diseases, and has clinical practical value.

The invention relates to the field of biological medicine, and discloses external cream capable of relieving post-traumatic bone joint degeneration pain symptoms and a preparation method of the external cream. By constructing a posttraumatic osteoarthritis rat model, it is found that experimental rats applying the atractylenolide I ointment group are superior to a control group in the aspects of behavioral analysis, bone mineral content, pain conduction and the like. According to the research, the suspension latex preparation containing atractylenolide particles is prepared from the Chinese herbal medicine extract atractylenolide I through an advanced medicine preparation process for the first time and is used for epidermis joints of lower limbs and the like. The composition can be used for improving arthralgia symptoms caused by joint degeneration after trauma, and an experimental foundation is laid for follow-up research of related drugs.